Pricing Log in Create free account
Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−51.5%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.28 0.29 −0.43%
Market cap
$39.0B
P/E
44.8×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Royalty Pharma PLC 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 9:02 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 6, 2026: 39 added · 16 removed · 62 modified; 10 with only figures updated

  1. Modified · Total income and other revenues

    Total income and other revenues is primarily comprised of interest income from our financial royalty assets and royalty income generally arising from successful commercialization of products developed through research and development (“R&D”) funding arrangementsagreements. Most of our royalties are classified as financial assets as our ownership rights are generally passive in nature.

116 more changes in this Item, word by word, in Powerpack.